A GIP, GLP-1 and glucagon receptor agonist studied in metabolic and body-weight research.
In simple words
Retatrutide is a research peptide that acts on GIP, GLP-1 and glucagon receptors. Researchers study these three hormone-signalling pathways in relation to metabolism and body weight.
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
338 adults with obesity or overweight and a related condition.
The trial studied a GIP, GLP-1 and glucagon receptor agonist and reported greater weight reduction than placebo over 48 weeks.
Gastrointestinal adverse events and increases in heart rate occurred. Findings concern the trial formulation, not this vial, and do not establish long-term safety.
PMID 37366315. Indexed abstract checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Resources
Identity search; no unambiguous compound record assigned to this listing. Check forms and synonyms carefully.
Evidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Research questions about Retatrutide (Reta)
What is Retatrutide (Reta)?
Retatrutide is a research peptide that acts on GIP, GLP-1 and glucagon receptors. Researchers study these three hormone-signalling pathways in relation to metabolism and body weight.
What types of research are cited for Retatrutide (Reta)?
The Retatrutide (Reta) profile contains the following selected evidence. This is not a systematic review or a complete inventory of research.
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
What do the selected Retatrutide (Reta) studies not establish?
Retatrutide: phase 2 obesity trial (2023): Gastrointestinal adverse events and increases in heart rate occurred. Findings concern the trial formulation, not this vial, and do not establish long-term safety.
These studies do not establish the identity, purity, safety or effects of the MXC Retatrutide (Reta) vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.